A detailed history of Vanguard Group Inc transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 8,555,597 shares of EDIT stock, worth $40 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,555,597
Previous 8,461,857 1.11%
Holding current value
$40 Million
Previous $85.7 Million 25.94%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$7.03 - $11.07 $658,992 - $1.04 Million
93,740 Added 1.11%
8,555,597 $63.5 Million
Q4 2023

Feb 14, 2024

SELL
$6.25 - $11.11 $464,693 - $826,039
-74,351 Reduced 0.87%
8,461,857 $85.7 Million
Q3 2023

Nov 14, 2023

BUY
$6.92 - $9.31 $2.57 Million - $3.45 Million
370,734 Added 4.54%
8,536,208 $66.6 Million
Q2 2023

Aug 14, 2023

BUY
$6.36 - $11.47 $6.12 Million - $11 Million
962,760 Added 13.37%
8,165,474 $67.2 Million
Q1 2023

Jul 14, 2023

BUY
$7.03 - $11.53 $21,090 - $34,590
3,000 Added 0.04%
7,202,714 $52.2 Million
Q1 2023

May 15, 2023

BUY
$7.03 - $11.53 $2.3 Million - $3.77 Million
326,591 Added 4.75%
7,199,714 $52.2 Million
Q4 2022

Feb 10, 2023

BUY
$8.32 - $13.21 $1.23 Million - $1.95 Million
147,783 Added 2.2%
6,873,123 $61 Million
Q3 2022

Nov 14, 2022

BUY
$12.16 - $19.42 $1.09 Million - $1.74 Million
89,730 Added 1.35%
6,725,340 $82.3 Million
Q2 2022

Aug 12, 2022

SELL
$9.99 - $21.35 $2.41 Million - $5.14 Million
-240,929 Reduced 3.5%
6,635,610 $78.5 Million
Q1 2022

May 13, 2022

BUY
$14.08 - $27.63 $2.85 Million - $5.6 Million
202,642 Added 3.04%
6,876,539 $131 Million
Q4 2021

Feb 14, 2022

BUY
$26.55 - $40.57 $6.13 Million - $9.36 Million
230,747 Added 3.58%
6,673,897 $177 Million
Q3 2021

Nov 12, 2021

SELL
$39.27 - $72.94 $1.6 Million - $2.97 Million
-40,782 Reduced 0.63%
6,443,150 $265 Million
Q2 2021

Aug 13, 2021

BUY
$31.29 - $56.64 $203 Million - $367 Million
6,483,932 New
6,483,932 $367 Million

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $321M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.